140 withdrawn. 140 Phase 2, 27 Phase 3, 24 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 140 | Withdrawn 140 |
| Phase 3 | 27 | Withdrawn 27 |
| Phase 1 | 24 | Withdrawn 24 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS Human umbilical cord mesenchymal stem cells + best supportive care, Placebo control + best supportive care - COVID-19, ARDS | Phase 1 / Phase 2 | Withdrawn | Baylx Inc. | 2026-06-01 | 2025-12-29 | |
| Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome Instilled T3, Placebo Therapy - Covid19, SARS-CoV Infection | Phase 2 | Withdrawn | University of Minnesota | 2026-01-15 | 2026-02-10 | |
| A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling - Long COVID, Post-Acute COVID-19 Syndrome | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2025-06-01 | 2025-08-26 | |
| Community-based Behavioral Intervention to Increase Vaccination Using MOST Health education on COVID and flu vaccination, Nurse-led shared decision-making, Text messages - COVID 19, Influenza | Phase 2 | Withdrawn | New York University | 2025-04-01 | 2025-04-29 | |
| Lot Consistency Study of COVID-19 and Influenza Combination Vaccine coformulated CIC Vaccine, Fluzone HD trivalent - COVID-19, Influenza | Phase 2 / Phase 3 | Withdrawn | Novavax | 2025-02-01 | 2025-03-11 | |
| ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles, Saline - Covid19, Postviral Syndrome | Phase 1 / Phase 2 | Withdrawn | Direct Biologics, LLC | 2024-11-01 | 2024-11-22 | |
| Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine tNIV 1 and Matrix-M Adjuvant - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Novavax | 2024-11-01 | 2025-03-11 | |
| Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19 TTI-0102, Placebo - COVID-19, COVID-19 Acute Respiratory Distress Syndrome | Phase 2 | Withdrawn | Thiogenesis Therapeutics, Inc. | 2024-09-27 | 2024-10-01 | |
| Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents Recombinant COVID-19 vaccine (Sf9 cells), Placebo control - COVID-19 | Phase 1 / Phase 2 | Withdrawn | WestVac Biopharma Co., Ltd. | 2024-07-01 | 2025-03-28 | |
| Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise COVI-MSC, Placebo - Covid19 | Phase 2 | Withdrawn | Sorrento Therapeutics, Inc. | 2024-02-01 | 2024-04-17 | |
| Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Pregnant Women TURKOVAC - COVID-19, SARS CoV 2 Infection | Phase 2 | Withdrawn | Health Institutes of Turkey | 2024-01-01 | 2025-05-30 | |
| The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19 Adenosine - Acute Respiratory Distress | Phase 2 | Withdrawn | University of Florida | 2023-12-01 | 2024-05-06 | |
| A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS Augmentin ES - Infections, Bacterial | Phase 2 | Withdrawn | GlaxoSmithKline | 2023-10-14 | 2025-03-28 | |
| COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients EP-7041 Injection - Thrombopenia, Covid19 | Phase 2 | Withdrawn | eXIthera Pharmaceuticals | 2023-10-01 | 2023-10-05 | |
| Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL EVUSHELD - Chronic Lymphocytic Leukemia, COVID-19 | Phase 2 | Withdrawn | Sunnybrook Health Sciences Centre | 2023-10-01 | 2024-04-04 | |
| Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19) Unfractionated Heparin - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Australian National University | 2023-08-01 | 2024-02-26 | |
| Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster Recombinant COVID-19 variant Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated, mRNA COVID-19 vaccine (Moderna) - COVID-19, SARS-CoV-2 Infection | Phase 2 | Withdrawn | WestVac Biopharma Co., Ltd. | 2023-07-07 | 2025-03-28 | |
| LACTYFERRIN™ Forte and ZINC Defense™ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19 Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™, Placebo - COVID-19 | Phase 2 | Withdrawn | Jose David Suarez, MD | 2023-06-01 | 2023-11-13 | |
| Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19 UC-MSCs - Long COVID-19 | Phase 2 | Withdrawn | Shanghai East Hospital | 2023-04-01 | 2023-11-21 |
Showing 20 of 140. Sign in to see all of them.
COVID-19 (132) · Coronavirus Infections (19) · Respiratory Distress Syndrome (9) · Cytokine Release Syndrome (4) · Pneumonia, Viral (4) · Respiratory Insufficiency (4) · Acute Lung Injury (3) · Community-Acquired Pneumonia (3) · Influenza, Human (3) · Lung Diseases (3) · Lymphoma, Follicular (3) · Post-Acute COVID-19 Syndrome (3) · Severe Acute Respiratory Syndrome (3) · Bacterial Infections (2)
Infections (139) · Respiratory Tract Diseases (138) · Respiratory Tract Infections (138) · Lung Diseases (135) · RNA Virus Infections (134) · Coronaviridae Infections (133) · Nidovirales Infections (133) · Virus Diseases (132) · Pneumonia, Viral (130) · Coronavirus Infections (115) · Pathological Conditions, Signs and Symptoms (17) · Pathologic Processes (12) · Respiration Disorders (12) · Hemic and Lymphatic Diseases (9)
Hydroxychloroquine (11) · STI-2020 (5) · Standard of Care (4) · Azithromycin (3) · Ascorbic Acid (2) · BNT162 Vaccine (2) · COVID-19 Vaccines (2) · Influenza Vaccines (2) · Melatonin (2) · Ritonavir (2) · SCB-2019 COVID-19 vaccine (2) · SCTV01C vaccine (2) · Saline Solution (2) · Sodium Chloride (2) · Tranexamic Acid (2)
Sorrento Therapeutics, Inc. (9) · ImmunityBio, Inc. (3) · Novavax (3) · Sinocelltech Ltd. (3) · University of Colorado, Denver (3) · Azidus Brasil (2) · Clover Biopharmaceuticals AUS Pty (2) · Direct Biologics, LLC (2) · Health Institutes of Turkey (2) · Pfizer (2) · Stanford University (2) · University of Alabama at Birmingham (2) · University of Texas Southwestern Medical Center (2) · Washington University School of Medicine (2) · WestVac Biopharma Co., Ltd. (2)
United States (38) · China (7) · France (4) · Canada (3) · Germany (3) · United Kingdom (3) · Australia (2) · Brazil (2) · Bulgaria (2) · India (2) · Italy (2) · Mexico (2) · Turkey (Türkiye) (2) · Colombia (1) · Israel (1)
Mike Royal, MD (9) · Bill Arana (2) · Fengcai Zhu (2) · Joaquin Espinosa, PhD (2) · Kevin V Grimes, MD (2) · Adrian Camacho Ortiz, MD (1) · Alpesh Amin, MD (1) · Amy Mathews, M.D. (1) · Andy Peniket (1) · Arya Mani, MD (1) · Asher Tal, MD (1) · Blaise Genton, MD-PhD (1) · Bruce Montgomery, M.D. (1) · Bruce Spiess (1)
PMID 34473343, PMID 35713300, PMID 32650818, PMID 34074163, PMID 35313959
UL1TR001412 (1)